" What lies behind us, what lies before us, are small matters compared to what lies within us" R.W. Emmerson
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Happy Mothers day...
Happy Mothers day.. just got back from a great brunch with my wife and daughter,, what a GREAT DAY...
Matt...how do I get out of this here jail... I am new to town,,can I make my call?.. For real.. How do I get back on the boards...
Good Morning all... I went out last night.. and woke up in here.. go figure.. what do I do to get out... if its bond money... whats the amount of the bail??????
HBSC... NICEEEEEEEEEEEEEEE .25x.258
L2
http://www.tradersnation.com/quote.shtml
L2 on HBSC..
http://www.tradersnation.com/quote.shtml
everyone have a good night
everyone have a good night
hbsc .21x.22 5MM on the bid at .21 good bid support...
HBSC.. .21x.22 5 MM on the bid at .21 nice buy at this leve;l.. imho...
HBSc .216x.24 nice paly at this level.. 5MM at bid .21
HBSc litle puch here at thios level... will make NICE up tick imo
HBSC... strong buy at this level... .216x.24 5 MM ion bid at .21
HBSC... .216x.24 5 MM on the bid at .21
anyone in here in HBSC.. breal out is ,225 I have added 45k more shares today.. going in for another 45k.. any help here.... break out is .225 and it is a easy .35++++
anyone in HBSC here... break out is .225 czn I see some hands here...
Press Release Source: Human BioSystems
U.S. Patent Office Grants Human BioSystems Its Third Patent: U.S. Patent #7/029,839, 'Methods & Solutions for Storing Donor Organs'
Wednesday May 10, 10:30 am ET
PALO ALTO, CALIFORNIA--(MARKET WIRE)--May 10, 2006 -- Human BioSystems (OTC BB:HBSC.OB - News), developer of preservation platforms for organs and other biomaterials, announced today that the U.S. Patent Office approved its patent for organ preservation entitled "Methods and Solutions for Storing Donor Organs" U.S. patent number 7/029,839. The current shelf-life of human donor organs is very short -- depending upon the organ, they must be transplanted within 3 to 36 hours. While maintaining viability, quality and safety, the Human BioSystems technology is designed to extend the shelf life of these organs longer than is now possible.
"We believe that Human BioSystems is the first to fill a current need of the medical community by providing a method of organ preservation that is estimated to save millions of dollars each year in anti-rejection drugs alone as a result having more time to have a better donor/recipient match. With more than 173,000 patients on transplant waiting lists, this new organ preservation technology can save untold lives. Longer shelf life of organs should benefit patients, surgeons, hospitals and insurance companies," explained Luis Toledo, MD, Chief Medical Officer of Human BioSystems.
Human BioSystems has two earlier approved patents: "Method & Apparatus for Preserving Biological Materials," US patent no. 6,413,713, and "Methods and Apparatuses for Preserving Platelets," U.S. Patent No. 6,828,090.
"With the granting of this third patent, we are confident that we will have more possibilities to continue to secure strategic alliances of partners as we progress through our testing phases," stated David Winter, MD, President of Human BioSystems.
HBS is headquartered in Palo Alto, California with research facilities in Michigan.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contact:
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
Yes International
Rich Kaiser
Investor Relations
(800) 631-8127
rich@yesinternational.com
Source: Human BioSystems
Press Release Source: Human BioSystems
U.S. Patent Office Grants Human BioSystems Its Third Patent: U.S. Patent #7/029,839, 'Methods & Solutions for Storing Donor Organs'
Wednesday May 10, 10:30 am ET
PALO ALTO, CALIFORNIA--(MARKET WIRE)--May 10, 2006 -- Human BioSystems (OTC BB:HBSC.OB - News), developer of preservation platforms for organs and other biomaterials, announced today that the U.S. Patent Office approved its patent for organ preservation entitled "Methods and Solutions for Storing Donor Organs" U.S. patent number 7/029,839. The current shelf-life of human donor organs is very short -- depending upon the organ, they must be transplanted within 3 to 36 hours. While maintaining viability, quality and safety, the Human BioSystems technology is designed to extend the shelf life of these organs longer than is now possible.
"We believe that Human BioSystems is the first to fill a current need of the medical community by providing a method of organ preservation that is estimated to save millions of dollars each year in anti-rejection drugs alone as a result having more time to have a better donor/recipient match. With more than 173,000 patients on transplant waiting lists, this new organ preservation technology can save untold lives. Longer shelf life of organs should benefit patients, surgeons, hospitals and insurance companies," explained Luis Toledo, MD, Chief Medical Officer of Human BioSystems.
Human BioSystems has two earlier approved patents: "Method & Apparatus for Preserving Biological Materials," US patent no. 6,413,713, and "Methods and Apparatuses for Preserving Platelets," U.S. Patent No. 6,828,090.
"With the granting of this third patent, we are confident that we will have more possibilities to continue to secure strategic alliances of partners as we progress through our testing phases," stated David Winter, MD, President of Human BioSystems.
HBS is headquartered in Palo Alto, California with research facilities in Michigan.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contact:
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
Yes International
Rich Kaiser
Investor Relations
(800) 631-8127
rich@yesinternational.com
Source: Human BioSystems
Press Release Source: Human BioSystems
U.S. Patent Office Grants Human BioSystems Its Third Patent: U.S. Patent #7/029,839, 'Methods & Solutions for Storing Donor Organs'
Wednesday May 10, 10:30 am ET
PALO ALTO, CALIFORNIA--(MARKET WIRE)--May 10, 2006 -- Human BioSystems (OTC BB:HBSC.OB - News), developer of preservation platforms for organs and other biomaterials, announced today that the U.S. Patent Office approved its patent for organ preservation entitled "Methods and Solutions for Storing Donor Organs" U.S. patent number 7/029,839. The current shelf-life of human donor organs is very short -- depending upon the organ, they must be transplanted within 3 to 36 hours. While maintaining viability, quality and safety, the Human BioSystems technology is designed to extend the shelf life of these organs longer than is now possible.
"We believe that Human BioSystems is the first to fill a current need of the medical community by providing a method of organ preservation that is estimated to save millions of dollars each year in anti-rejection drugs alone as a result having more time to have a better donor/recipient match. With more than 173,000 patients on transplant waiting lists, this new organ preservation technology can save untold lives. Longer shelf life of organs should benefit patients, surgeons, hospitals and insurance companies," explained Luis Toledo, MD, Chief Medical Officer of Human BioSystems.
Human BioSystems has two earlier approved patents: "Method & Apparatus for Preserving Biological Materials," US patent no. 6,413,713, and "Methods and Apparatuses for Preserving Platelets," U.S. Patent No. 6,828,090.
"With the granting of this third patent, we are confident that we will have more possibilities to continue to secure strategic alliances of partners as we progress through our testing phases," stated David Winter, MD, President of Human BioSystems.
HBS is headquartered in Palo Alto, California with research facilities in Michigan.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contact:
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
Yes International
Rich Kaiser
Investor Relations
(800) 631-8127
rich@yesinternational.com
Source: Human BioSystems
Press Release Source: Strategic Growth Ventures, Inc.
Strategic Growth Ventures Announces Launch of Online Travel Site: GetCash4Travel.com Powered by Priceline
Monday February 27, 11:57 am ET
TAMPA, Fla.--(BUSINESS WIRE)--Feb. 27, 2006--Today Strategic Growth Ventures (Pink Sheets:SGWV - News) announced the launch of GetCashForTravel.com, an online travel site offering booking for flights, cars, hotels, cruises and vacations where registered users can become their own travel agents and literally get paid a commission each time they or registered users under them book travel through the site.
GetCash4Travel.com (www.ytbnet.com/sgwvtravel) is a registered agent with the YTB Travel Network, a wholly owned subsidiary of YTB International, Inc. (OTCBB:YTBL - News) and powered by Priceline.com (Nasdaq:PCLN - News). GetCash4Travel.com will offer a product that takes full advantage of the hottest trend "Travel". Registered users of the site can book travel at the site or sign up to become their own travel agents and begin earning commissions immediately on any travel booked through their site.
"We are very excited to bring this business opportunity to potentially millions of online users who book travel online to not only have access to some of the best travel deals in the industry but to also start their own independent, web-based travel business," says Mike Elliott, CEO of Strategic Growth Ventures.
Travel is the world's largest, fastest growing industry, currently at $5 TRILLION each year, and growing 23% faster than the global economy. Travel is expected to double to $10 TRILLION by the end of the decade. The average American spends $2,800 each year on vacations.
About Strategic Growth Ventures: Strategic Growth Ventures, Inc. invests in emerging growth companies with market-ready products, strong management teams, and strategies for developing high growth companies in well defined markets.
Statements regarding financial matters in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements be subject to the safe harbors created thereby. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results.
Contact:
Strategic Growth Ventures, Inc., Tampa
Mike Elliott, 813-223-7788
Source: Strategic Growth Ventures, Inc.
Press Release Source: Strategic Growth Ventures, Inc.
Strategic Growth Ventures Announces Launch of Online Travel Site: GetCash4Travel.com Powered by Priceline
Monday February 27, 11:57 am ET
TAMPA, Fla.--(BUSINESS WIRE)--Feb. 27, 2006--Today Strategic Growth Ventures (Pink Sheets:SGWV - News) announced the launch of GetCashForTravel.com, an online travel site offering booking for flights, cars, hotels, cruises and vacations where registered users can become their own travel agents and literally get paid a commission each time they or registered users under them book travel through the site.
GetCash4Travel.com (www.ytbnet.com/sgwvtravel) is a registered agent with the YTB Travel Network, a wholly owned subsidiary of YTB International, Inc. (OTCBB:YTBL - News) and powered by Priceline.com (Nasdaq:PCLN - News). GetCash4Travel.com will offer a product that takes full advantage of the hottest trend "Travel". Registered users of the site can book travel at the site or sign up to become their own travel agents and begin earning commissions immediately on any travel booked through their site.
"We are very excited to bring this business opportunity to potentially millions of online users who book travel online to not only have access to some of the best travel deals in the industry but to also start their own independent, web-based travel business," says Mike Elliott, CEO of Strategic Growth Ventures.
Travel is the world's largest, fastest growing industry, currently at $5 TRILLION each year, and growing 23% faster than the global economy. Travel is expected to double to $10 TRILLION by the end of the decade. The average American spends $2,800 each year on vacations.
About Strategic Growth Ventures: Strategic Growth Ventures, Inc. invests in emerging growth companies with market-ready products, strong management teams, and strategies for developing high growth companies in well defined markets.
Statements regarding financial matters in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The company intends that such statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements be subject to the safe harbors created thereby. Since these statements (future operational results and sales) involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results.
Contact:
Strategic Growth Ventures, Inc., Tampa
Mike Elliott, 813-223-7788
Source: Strategic Growth Ventures, Inc.
U.S. Patent Office Grants Human BioSystems Its Third Patent: U.S. Patent #7/029,839, 'Methods & Solutions for Storing Donor Organs'
Wednesday May 10, 10:30 am ET
PALO ALTO, CALIFORNIA--(MARKET WIRE)--May 10, 2006 -- Human BioSystems (OTC BB:HBSC.OB - News), developer of preservation platforms for organs and other biomaterials, announced today that the U.S. Patent Office approved its patent for organ preservation entitled "Methods and Solutions for Storing Donor Organs" U.S. patent number 7/029,839. The current shelf-life of human donor organs is very short -- depending upon the organ, they must be transplanted within 3 to 36 hours. While maintaining viability, quality and safety, the Human BioSystems technology is designed to extend the shelf life of these organs longer than is now possible.
"We believe that Human BioSystems is the first to fill a current need of the medical community by providing a method of organ preservation that is estimated to save millions of dollars each year in anti-rejection drugs alone as a result having more time to have a better donor/recipient match. With more than 173,000 patients on transplant waiting lists, this new organ preservation technology can save untold lives. Longer shelf life of organs should benefit patients, surgeons, hospitals and insurance companies," explained Luis Toledo, MD, Chief Medical Officer of Human BioSystems.
Human BioSystems has two earlier approved patents: "Method & Apparatus for Preserving Biological Materials," US patent no. 6,413,713, and "Methods and Apparatuses for Preserving Platelets," U.S. Patent No. 6,828,090.
"With the granting of this third patent, we are confident that we will have more possibilities to continue to secure strategic alliances of partners as we progress through our testing phases," stated David Winter, MD, President of Human BioSystems.
HBS is headquartered in Palo Alto, California with research facilities in Michigan.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contact:
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
Yes International
Rich Kaiser
Investor Relations
(800) 631-8127
rich@yesinternational.com
Source: Human BioSystems
HBSC.. pick at .60+ break out is .255 .23x.248...
U.S. Patent Office Grants Human BioSystems Its Third Patent: U.S. Patent #7/029,839, 'Methods & Solutions for Storing Donor Organs'
Wednesday May 10, 10:30 am ET
PALO ALTO, CALIFORNIA--(MARKET WIRE)--May 10, 2006 -- Human BioSystems (OTC BB:HBSC.OB - News), developer of preservation platforms for organs and other biomaterials, announced today that the U.S. Patent Office approved its patent for organ preservation entitled "Methods and Solutions for Storing Donor Organs" U.S. patent number 7/029,839. The current shelf-life of human donor organs is very short -- depending upon the organ, they must be transplanted within 3 to 36 hours. While maintaining viability, quality and safety, the Human BioSystems technology is designed to extend the shelf life of these organs longer than is now possible.
"We believe that Human BioSystems is the first to fill a current need of the medical community by providing a method of organ preservation that is estimated to save millions of dollars each year in anti-rejection drugs alone as a result having more time to have a better donor/recipient match. With more than 173,000 patients on transplant waiting lists, this new organ preservation technology can save untold lives. Longer shelf life of organs should benefit patients, surgeons, hospitals and insurance companies," explained Luis Toledo, MD, Chief Medical Officer of Human BioSystems.
Human BioSystems has two earlier approved patents: "Method & Apparatus for Preserving Biological Materials," US patent no. 6,413,713, and "Methods and Apparatuses for Preserving Platelets," U.S. Patent No. 6,828,090.
"With the granting of this third patent, we are confident that we will have more possibilities to continue to secure strategic alliances of partners as we progress through our testing phases," stated David Winter, MD, President of Human BioSystems.
HBS is headquartered in Palo Alto, California with research facilities in Michigan.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contact:
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
Yes International
Rich Kaiser
Investor Relations
(800) 631-8127
rich@yesinternational.com
Source: Human BioSystems
.23x.248 BREAK OUT at .255 bring in the troops... .35-.40 is right around the conner
.24x.248... break out at .25 who is in the stock.. rally needed I jsut picked up another 35K at .235 and .243 and .245
I have reasone to believe more news is coming our way... imo eom
HBSC.. .24x.248
vol buys coming in HBSC .23x.245
HBSC.. .235.243 little vol witl KICK THIS thing off...
HBSC.. .23x.235 HBSC vol spike yesterday 55%-20-adsv, stock +8.70% yesterday.. more news on its way I have reasone to believe
Market News
--------------------------------------------------------------------------------
HBSC
--------------------------------------------------------------------------------
HBSC: Volume Spike; 55% > 20-adsv, Stock +8.70%
WEDNESDAY, MAY 10, 2006 11:05 AM
This is the 1st VOLUME alert for HBSC in the past 7 calendar days.
Trading for Human BioSystems (OTCBB: HBSC) has been heavier than usual in today's session. By 11:05 ET, the stock had already traded 330,500 shares via 18 trades. The cumulative volume is 55.28% above its 20-day average of 212,836. Normally the stock experiences around 21 individual trades per session.
So far, today's volume surge has caused a net rise in HBSC's stock price. At the time of this alert, the stock was trading at $0.250, up $0.020 (+8.70%).
One year ago, the Company's shares closed at $0.400. The price has declined more than 37 percent since then.
Over the last 10 trading session HBSC has traded in a range between
$0.210 and $0.320 and is currently trading 77.27% below its
52-week high of $1.100 set on June 30,2005 and 19.05% above its
52-week low of $0.210 from May 04,2006.
In the previous 3 sessions, HBSC trading has displayed a mixed trend. Closing results have been as follows:
May 09, 2006 --- closed at $0.230 down $0.005 (-2.13%) on 181,600 shares
May 08, 2006 --- closed at $0.235 even for the day on 72,720 shares
May 05, 2006 --- closed at $0.235 up $0.005 (+2.17%) on 131,900 shares
The Company last released news on April 05, 2006:
"HBSC and HEB Update the Investment Community in All-New Interviews With www.wallst.net"
HUMAN BIOSYSTEMS
Human BioSystems(formerly Hyperbaric Systems) has been a developmental stage company with operations related to medical research and discovery. The Company's objective has been to develop and provide a product that extends the shelf life and improves the quality of blood platelets and other biological material.
--------------------------------------------------------------------------------
Copyright © 2002. The Nasdaq Stock Market, Inc
Copyright ©2002 Knobias.com, LLC
Market News
--------------------------------------------------------------------------------
HBSC
--------------------------------------------------------------------------------
HBSC: Volume Spike; 55% > 20-adsv, Stock +8.70%
WEDNESDAY, MAY 10, 2006 11:05 AM
This is the 1st VOLUME alert for HBSC in the past 7 calendar days.
Trading for Human BioSystems (OTCBB: HBSC) has been heavier than usual in today's session. By 11:05 ET, the stock had already traded 330,500 shares via 18 trades. The cumulative volume is 55.28% above its 20-day average of 212,836. Normally the stock experiences around 21 individual trades per session.
So far, today's volume surge has caused a net rise in HBSC's stock price. At the time of this alert, the stock was trading at $0.250, up $0.020 (+8.70%).
One year ago, the Company's shares closed at $0.400. The price has declined more than 37 percent since then.
Over the last 10 trading session HBSC has traded in a range between
$0.210 and $0.320 and is currently trading 77.27% below its
52-week high of $1.100 set on June 30,2005 and 19.05% above its
52-week low of $0.210 from May 04,2006.
In the previous 3 sessions, HBSC trading has displayed a mixed trend. Closing results have been as follows:
May 09, 2006 --- closed at $0.230 down $0.005 (-2.13%) on 181,600 shares
May 08, 2006 --- closed at $0.235 even for the day on 72,720 shares
May 05, 2006 --- closed at $0.235 up $0.005 (+2.17%) on 131,900 shares
The Company last released news on April 05, 2006:
"HBSC and HEB Update the Investment Community in All-New Interviews With www.wallst.net"
HUMAN BIOSYSTEMS
Human BioSystems(formerly Hyperbaric Systems) has been a developmental stage company with operations related to medical research and discovery. The Company's objective has been to develop and provide a product that extends the shelf life and improves the quality of blood platelets and other biological material.
--------------------------------------------------------------------------------
Copyright © 2002. The Nasdaq Stock Market, Inc
Copyright ©2002 Knobias.com, LLC
Market News
--------------------------------------------------------------------------------
HBSC
--------------------------------------------------------------------------------
HBSC: Volume Spike; 55% > 20-adsv, Stock +8.70%
WEDNESDAY, MAY 10, 2006 11:05 AM
This is the 1st VOLUME alert for HBSC in the past 7 calendar days.
Trading for Human BioSystems (OTCBB: HBSC) has been heavier than usual in today's session. By 11:05 ET, the stock had already traded 330,500 shares via 18 trades. The cumulative volume is 55.28% above its 20-day average of 212,836. Normally the stock experiences around 21 individual trades per session.
So far, today's volume surge has caused a net rise in HBSC's stock price. At the time of this alert, the stock was trading at $0.250, up $0.020 (+8.70%).
One year ago, the Company's shares closed at $0.400. The price has declined more than 37 percent since then.
Over the last 10 trading session HBSC has traded in a range between
$0.210 and $0.320 and is currently trading 77.27% below its
52-week high of $1.100 set on June 30,2005 and 19.05% above its
52-week low of $0.210 from May 04,2006.
In the previous 3 sessions, HBSC trading has displayed a mixed trend. Closing results have been as follows:
May 09, 2006 --- closed at $0.230 down $0.005 (-2.13%) on 181,600 shares
May 08, 2006 --- closed at $0.235 even for the day on 72,720 shares
May 05, 2006 --- closed at $0.235 up $0.005 (+2.17%) on 131,900 shares
HUMAN BIOSYSTEMS
Human BioSystems(formerly Hyperbaric Systems) has been a developmental stage company with operations related to medical research and discovery. The Company's objective has been to develop and provide a product that extends the shelf life and improves the quality of blood platelets and other biological material.
--------------------------------------------------------------------------------
Copyright © 2002. The Nasdaq Stock Market, Inc
Copyright ©2002 Knobias.com, LLC
HBSC.. .23x.245
HBSC.. .23x.245 baby wake ing up... .26 after that.. lets break thru the .25 level sky the limit... go HBSC.. go
HBSC... majior play today..imo n.23x.24
http://biz.yahoo.com/e/060510/hbsc.ob8-k.html
HBSC today is HUGE BUY..imo news released yesterday at the close.... .25 break out on this stock... .23x.24... 4 market makers on bid at .21 5 market makers on bid at .20 solid bid support
http://biz.yahoo.com/e/060510/hbsc.ob8-k.html
Press Release Source: Human BioSystems
U.S. Patent Office Grants Human BioSystems Its Third Patent: U.S. Patent #7/029,839, 'Methods & Solutions for Storing Donor Organs'
Wednesday May 10, 10:30 am ET
PALO ALTO, CALIFORNIA--(MARKET WIRE)--May 10, 2006 -- Human BioSystems (OTC BB:HBSC.OB - News), developer of preservation platforms for organs and other biomaterials, announced today that the U.S. Patent Office approved its patent for organ preservation entitled "Methods and Solutions for Storing Donor Organs" U.S. patent number 7/029,839. The current shelf-life of human donor organs is very short -- depending upon the organ, they must be transplanted within 3 to 36 hours. While maintaining viability, quality and safety, the Human BioSystems technology is designed to extend the shelf life of these organs longer than is now possible.
"We believe that Human BioSystems is the first to fill a current need of the medical community by providing a method of organ preservation that is estimated to save millions of dollars each year in anti-rejection drugs alone as a result having more time to have a better donor/recipient match. With more than 173,000 patients on transplant waiting lists, this new organ preservation technology can save untold lives. Longer shelf life of organs should benefit patients, surgeons, hospitals and insurance companies," explained Luis Toledo, MD, Chief Medical Officer of Human BioSystems.
Human BioSystems has two earlier approved patents: "Method & Apparatus for Preserving Biological Materials," US patent no. 6,413,713, and "Methods and Apparatuses for Preserving Platelets," U.S. Patent No. 6,828,090.
"With the granting of this third patent, we are confident that we will have more possibilities to continue to secure strategic alliances of partners as we progress through our testing phases," stated David Winter, MD, President of Human BioSystems.
HBS is headquartered in Palo Alto, California with research facilities in Michigan.
Certain statements contained herein are "forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the inability to find a strategic partner or to consummate a relationship with a potential strategic partner on acceptable terms, and other factors discussed in filings made by the Company with the Securities and Exchange Commission.
Contact:
Contacts:
Human BioSystems
Harry Masuda
CEO
(650) 323-0943
hmasuda@humanbiosystems.com
Yes International
Rich Kaiser
Investor Relations
(800) 631-8127
rich@yesinternational.com
--------------------------------------------------------------------------------
HBSC... .23x.24 look at this issue.. vol yesterday was a start break out is ,25 on this stock ..imo
http://biz.yahoo.com/e/060510/hbsc.ob8-k.html
HBSC .23x.24 vol yesterday was only a start..
http://biz.yahoo.com/e/060510/hbsc.ob8-k.html